Investigators conducted a retrospective study of patients treated for early-stage breast cancer at Fred Hutch Cancer Center to identify clinicopathologic factors associated with SLN-positivity (SLN+), ...

GLP-1 drugs, once scrutinised for possibly causing cancer, are now being discussed as drugs that might prevent or even treat ...

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January-June 2026 April-June 2026 Highlights Net sales totalled EUR 521.6 (April-June ...

Net sales totalled EUR 939.3 (January-June 2025: 771.0) million Operating profit was EUR 291.3 (182.5) million Basic earnings per share were EUR 1.64 (1.02) Cash flow from operating activities per ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

Evidence supports cannabis-based therapies for a limited number of conditions. Here’'s what clinicians should know — and tell ...

Investors have had a moment to digest what Tempus AI (NASDAQ:TEM) actually delivered when Q1 2026 results landed on May 5.

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...

Cancer is among the hardest diseases to study because it is not one disease but more than 100. Breast, lung and blood cancers ...

REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In ...